| Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target M Bolzoni, M Chiu, F Accardi, R Vescovini, I Airoldi, P Storti, K Todoerti, ... Blood, The Journal of the American Society of Hematology 128 (5), 667-679, 2016 | 168 | 2016 |
| Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic … S Colla, P Storti, G Donofrio, K Todoerti, M Bolzoni, M Lazzaretti, ... Leukemia 24 (11), 1967-1970, 2010 | 146 | 2010 |
| Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma‐induced alterations of bone remodeling F Accardi, D Toscani, M Bolzoni, B Dalla Palma, F Aversa, N Giuliani BioMed research international 2015 (1), 172458, 2015 | 137 | 2015 |
| Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation N Giuliani, M Ferretti, M Bolzoni, P Storti, M Lazzaretti, B Dalla Palma, ... Leukemia 26 (6), 1391-1401, 2012 | 136 | 2012 |
| Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction P Storti, M Bolzoni, G Donofrio, I Airoldi, D Guasco, D Toscani, E Martella, ... Leukemia 27 (8), 1697-1706, 2013 | 134 | 2013 |
| Angiogenesis and multiple myeloma N Giuliani, P Storti, M Bolzoni, BD Palma, S Bonomini Cancer microenvironment 4, 325-337, 2011 | 129 | 2011 |
| New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in … N Giuliani, G Lisignoli, M Magnani, C Racano, M Bolzoni, B Dalla Palma, ... Stem cells international 2013 (1), 312501, 2013 | 109 | 2013 |
| NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model AL Horenstein, A Chillemi, V Quarona, A Zito, I Roato, F Morandi, ... Cells 4 (3), 520-537, 2015 | 105 | 2015 |
| Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the … M Bolzoni, P Storti, S Bonomini, K Todoerti, D Guasco, D Toscani, ... Experimental hematology 41 (4), 387-397. e1, 2013 | 93 | 2013 |
| Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP … F Morandi, D Marimpietri, AL Horenstein, M Bolzoni, D Toscani, F Costa, ... Oncoimmunology 7 (8), e1458809, 2018 | 85 | 2018 |
| Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease K Todoerti, G Lisignoli, P Storti, L Agnelli, F Novara, C Manferdini, ... Experimental hematology 38 (2), 141-153, 2010 | 78 | 2010 |
| Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation F Costa, D Toscani, A Chillemi, V Quarona, M Bolzoni, V Marchica, ... Oncotarget 8 (34), 56598, 2017 | 66 | 2017 |
| Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic … M Bolzoni, G Donofrio, P Storti, D Guasco, D Toscani, M Lazzaretti, ... Leukemia 27 (2), 451-463, 2013 | 65 | 2013 |
| The osteoblastic niche in the context of multiple myeloma D Toscani, M Bolzoni, F Accardi, F Aversa, N Giuliani Annals of the New York Academy of Sciences 1335 (1), 45-62, 2015 | 64 | 2015 |
| HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients P Storti, G Donofrio, S Colla, I Airoldi, M Bolzoni, L Agnelli, M Abeltino, ... Leukemia 25 (3), 527-537, 2011 | 64 | 2011 |
| Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche V Quarona, V Ferri, A Chillemi, M Bolzoni, C Mancini, G Zaccarello, ... Annals of the New York Academy of Sciences 1335 (1), 10-22, 2015 | 62 | 2015 |
| Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma R Silbermann, M Bolzoni, P Storti, D Guasco, S Bonomini, D Zhou, J Wu, ... Leukemia 28 (4), 951-954, 2014 | 59 | 2014 |
| The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors D Toscani, C Palumbo, B Dalla Palma, M Ferretti, M Bolzoni, V Marchica, ... Journal of Bone and Mineral Research 31 (4), 815-827, 2016 | 57 | 2016 |
| Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (CC motif) ligand 20 B Dalla Palma, D Guasco, M Pedrazzoni, M Bolzoni, F Accardi, F Costa, ... Leukemia 30 (2), 409-416, 2016 | 57 | 2016 |
| IL21R expressing CD14+ CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts M Bolzoni, D Ronchetti, P Storti, G Donofrio, V Marchica, F Costa, ... Haematologica 102 (4), 773, 2017 | 44 | 2017 |
